Selank: The Russian-Made Heptapeptide and What Researchers Are Studying

Forty years ago, a group of biochemists at the Institute of Molecular Genetics in Moscow looked at a four-amino-acid fragment that human antibodies release into circulation, decided it was interesting but too fragile, and bolted three extra residues onto its tail to make it last longer. The resulting seven-amino-acid molecule — Selank — is still cited in published research today, and it sits at the intersection of immunology, neuroscience, and neurotrophin biology. Every Selank study we describe below is laboratory work in cell culture or rodents; the material is sold and shipped for research use only, and nothing in this article is medical advice. We've written before about BPC-157 and other peptides whose research story follows a similar shape: a molecule from biology, redesigned for the bench.

The Tuftsin Lineage: Where Selank Comes From

Selank's parent molecule is named tuftsin — a four-residue peptide with the sequence Thr-Lys-Pro-Arg, released from the Fc tail of immunoglobulin G when phagocytic enzymes clip it free. Tuftsin matters historically because it was one of the first proteins shown to fall out of an antibody and then go on to tell white blood cells what to do. That made it an early concrete example of the immune system carrying chemical messages, not just antibodies themselves.

The Russian group at the Institute of Molecular Genetics worked on a practical design problem. Tuftsin behaves the way they wanted in test tubes, but the body chews it apart in minutes. Their fix was to extend the molecule at the C-terminus with three more amino acids — proline, glycine, and another proline — giving the full Selank sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Those proline residues are doing a specific job: their rigid pyrrolidine ring is a well-known steric block to common peptidases, so the tail acts as a chemical bumper that keeps the active core intact longer than the parent peptide manages on its own. The published record of Selank's origin and primary sequence tracks back to that Moscow lab and a small body of late-1980s and 1990s biochemistry.

If the pattern of taking a biologically meaningful fragment and redesigning it for the bench sounds familiar, that's because it's widespread. MOTS-c, another peptide that escaped from an unusual corner of biology, is one more molecule researchers ended up studying in synthesised form for the same reason — the natural version is hard to work with at scale.

Why Pro-Gly-Pro? The Stability Question

Before any mechanism work means anything, a peptide has to actually be present long enough in a tissue or in a cell-culture dish for an effect to be measurable. Which is why one of the earliest published Selank studies was a pharmacokinetic profile in rats.

The rat pharmacokinetic paper tracks plasma and brain peptide levels following parenteral and intranasal application, and the headline number is a meaningful extension of measurable half-life compared with parent tuftsin. Tuftsin is gone within a few minutes of release in serum; Selank persists long enough to make cell-culture and in-vivo studies practical. Brain penetration in that paper was detectable but modest, which isn't surprising for a small, polar molecule of this kind.

That stability margin is part of why researchers use Selank as a tool compound at all. Without the Pro-Gly-Pro tail doing its job, every downstream effect described in this article would be even harder to attribute to the peptide itself, because the molecule wouldn't be around to act. The pharmacokinetic numbers also explain why most of the Selank literature uses rats and mice with a route-of-application chosen for that window — short experimental sessions, intranasal or parenteral.

The GABA Question: A Mechanism Researchers Are Still Mapping

Plain-English answer first: in rodents, Selank looks like it's touching the GABA system somewhere; in human-neuroblastoma cell culture, the same molecule doesn't move GABA-related gene expression at all. That mismatch is itself one of the most informative findings in the Selank literature.

On the rodent side, a 2016 hippocampal transcript study reports that intranasal Selank shifts mRNA levels for several GABA-A receptor subunits and for glutamate decarboxylase, the enzyme that synthesises GABA from glutamate. Effect size in that paper is modest, not transformational, and the authors interpret the pattern as compatible with allosteric facilitation of GABA-A signalling rather than direct receptor agonism. Direct agonists usually push the system harder.

Cross-check that against the cell-culture result. A Frontiers in Pharmacology paper exposed IMR-32 human neuroblastoma cells to Selank, GABA itself, and olanzapine at parallel concentrations. Selank produced no statistically reliable change in mRNA levels of GABA-A subunits or of GAD in this cell line. The authors took that as partial support for the hypothesis that whatever Selank is doing in the rodent brain, it isn't operating through neuronal transcription — the molecule is probably doing its work at the receptor protein, with downstream signal flowing through immune and neurotrophin pathways that a cell-culture monoculture can't model.

That cell-culture-versus-tissue gap is genuinely useful for narrowing the search. No published high-resolution structural snapshot of Selank bound to a GABA-A receptor exists yet. The mechanism the field is working with is consistent with allosteric receptor modulation; it isn't yet a closed case.

Echoes of Tuftsin: Selank's Immune-System Signature

Plain-English answer first: Selank kept its parent peptide's job as an immune signal, even after the C-terminal redesign. The cleanest evidence is in spleen-transcript profiling work in mice and rats.

A mouse-spleen 84-gene PCR-array study reports statistically significant shifts in 34 of the 84 inflammation-related transcripts profiled, after Selank exposure. The affected genes are enriched for chemokines, interleukins, and their receptors. A companion rat-spleen time-course paper tracks the same general signature across multiple timepoints, with the largest movement seen on interleukin-6 and several T-helper-cytokine balance markers.

Both groups frame their results carefully. Selank isn't coming through as either pro-inflammatory or anti-inflammatory in a clean sense — it's a modest, broad modulator that shifts the immune readout in a pattern resembling parent tuftsin rather than something dramatically new. That matters for understanding what the molecule is for, in research-tool terms: a compound that touches both immune signalling and central-nervous-system biology is exactly the kind of instrument researchers reach for when they want to interrogate the cross-talk between those two systems.

BDNF, Monoamines, and the Multi-Target Picture

Plain-English answer first: Selank doesn't have one job — it has several, and the cleanest way to read the literature is to expect a multi-target picture.

A 2019 rat ethanol-impairment study measured BDNF protein in hippocampus and prefrontal cortex after a stress protocol that lowers BDNF in untreated animals. Co-application of Selank attenuated both the BDNF drop and the deficit on a passive-avoidance memory task. BDNF — brain-derived neurotrophic factor — is the brain's standard-issue maintenance and plasticity signal, and even modest preservation of BDNF lines up with the memory-protective behavioural data.

Monoamines tell a related but stranger story. A BALB/c-versus-C57Bl/6 mouse comparison shows that the strain of mouse meaningfully changes what serotonin, dopamine, and noradrenaline turnover look like after Selank exposure. That's a strain-by-treatment interaction, and it means a single rodent answer is not all rodent answers; genetic background shapes the biochemical readout. Researchers reading the Selank literature have to take that variability into account before they call any single result the canonical one.

Add in a rat morphine-withdrawal model where Selank attenuates the aversive behavioural signs of withdrawal — plausibly through inhibition of enkephalin-degrading enzymes and a rise in local endogenous-opioid tone — and you have a molecule whose biochemical fingerprint spans GABA-A, BDNF, monoamines, and the enkephalin system. That isn't a clean single-target story, and the literature is honest about it. For readers who want a parallel example of an in-vitro mechanism story spreading across multiple signalling families, our TB-500 in-vitro work explainer walks through a similar pattern.

What the Behavioural Literature Actually Shows

Plain-English answer first: across roughly four decades of rodent stress and depression paradigms, Selank produces a recognisable, reproducible behavioural signature — and the signature looks more like a short-acting benzodiazepine than anything else, but without the motor or sedative profile a direct GABA-A agonist produces.

A long-running review of the tuftsin-family behavioural pharmacology covers the open-field test, the elevated-plus-maze, the forced-swim test, and conditioned-fear paradigms in rats and mice. The reproducible finding is an anxiolytic-like behavioural fingerprint of roughly the same magnitude as short-acting benzodiazepines, with one critical difference: no motor slowing and no overt sedation. That difference is part of why the receptor-binding mechanism story is interesting at all — a direct GABA-A agonist would be expected to drag along that side-effect profile.

On the depression-paradigm side, a multi-strain study in WAG/Rij rats, Wistar rats, and BALB/c mice describes lower immobility times and weaker learned-helplessness signatures across all three strains. As with the monoamine work, effect size depends on the rodent strain.

None of this is a clinical endpoint. These are rodent behavioural readouts in artificial stress paradigms, and the literature is consistent enough to make Selank a useful recurring tool compound in that line of research — but consistent rodent behavioural data isn't evidence that the molecule does the same thing in human beings. Researchers who write about Selank know the difference; readers should too.

Regulatory Status and the "Research Chemical" Reality

Inside Russia, Selank has been studied as a candidate anxiolytic and at times has been marketed as a pharmaceutical product. Outside Russia, that status doesn't carry over. The FDA has not approved Selank for any medical indication, and the molecule isn't sold as a medication anywhere in the United States. It moves through the U.S. supply chain only as a research chemical, labelled for research use only and not intended for human or animal consumption.

Anyone working with Selank in the U.S. is therefore working with a research chemical in a laboratory setting. The published literature we've been walking through is real, citable, and useful for understanding the molecule; the framing as a consumer product is not. If you want to know what the "research-grade" designation actually means in practical terms, we've written a separate piece on that exact question.

Frequently Asked Questions

What is Selank made of?

Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, an active fragment of human immunoglobulin G; the extra Pro-Gly-Pro tail is the part chemists added on purpose, so that common peptidases wouldn't strip the molecule apart as quickly as they do native tuftsin.

Why was Selank developed in Russia?

It came out of the Institute of Molecular Genetics at the Russian Academy of Sciences. That lab spent the late 1980s and the 1990s building synthetic stand-ins for endogenous regulatory peptides, and Selank is one of the molecules from that programme that ended up generating a continuing published research literature. The naming follows the lab's convention — short, memorable, and not tied to a marketing-driven brand.

Does Selank work the same way as a benzodiazepine?

Rodent studies describe a behavioural signature whose magnitude looks comparable to a short-acting benzodiazepine, but cell-culture data argue against direct GABA-A agonism. The mechanism researchers currently work with is allosteric receptor modulation plus downstream effects on the neurotrophin and monoamine systems — not the same molecular story as a benzodiazepine, even where the behavioural fingerprint looks similar.

Is Selank an FDA-approved medication?

No. Outside Russia, Selank is not approved for any medical indication. In the United States it is sold and shipped only as a research chemical, intended for laboratory work in cell-culture and animal-model studies in qualified facilities. Nothing in the published literature supports framing it as a consumer health product.

Conclusion

Selank is a tidy example of biology-derived chemistry — a four-residue piece of an antibody, extended by three extra amino acids so it could survive long enough to study, and then turned into a roughly forty-year thread of published research. What the literature has reasonably well established is the structure, the pharmacokinetic window, the immune-transcript signature inherited from parent tuftsin, the neurotrophin effect in stressed rodents, and a recognisable rodent behavioural fingerprint. What's still genuinely open is the precise receptor-binding story, the cell-culture-to-behaviour bridge, and any unification of the multi-target picture. For readers exploring related compounds, our BPC-157, TB-500, and MOTS-c explainers walk through similar territory. Selank remains a research chemical, studied in the laboratory, and not a consumer product.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.